BACKGROUND: Residual kidney function (RKF) is associated with improved survival in peritoneal dialysis patients, but its role in hemodialysis patients is less well known. Urine output may provide an estimate of RKF. The aim of our study is to determine the association of urine output with mortality, quality of life (QOL), and inflammation in incident hemodialysis patients. STUDY DESIGN: Nationally representative prospective cohort study. SETTING & PARTICIPANTS: 734 incident hemodialysis participants treated in 81 clinics; enrollment, 1995-1998; follow-up until December 2004. PREDICTOR: Urine output, defined as producing at least 250 mL (1 cup) of urine daily, ascertained using questionnaires at baseline and year 1. OUTCOMES & MEASUREMENTS: Primary outcomes were all-cause and cardiovascular mortality, analyzed using Cox regression adjusted for demographic, clinical, and treatment characteristics. Secondary outcomes were QOL, inflammation (C-reactive protein and interleukin 6 levels), and erythropoietin (EPO) requirements. RESULTS: 617 of 734 (84%) participants reported urine output at baseline, and 163 of 579 (28%), at year 1. Baseline urine output was not associated with survival. Urine output at year 1, indicating preserved RKF, was independently associated with lower all-cause mortality (HR, 0.70; 95% CI, 0.52-0.93; P = 0.02) and a trend toward lower cardiovascular mortality (HR, 0.69; 95% CI, 0.45-1.05; P = 0.09). Participants with urine output at baseline reported better QOL and had lower C-reactive protein (P = 0.02) and interleukin 6 (P = 0.03) levels. Importantly, EPO dose was 12,000 U/wk lower in those with urine output at year 1 compared with those without (P = 0.001). LIMITATIONS: Urine volume was measured in only a subset of patients (42%), but agreed with self-report (P < 0.001). CONCLUSIONS: RKF in hemodialysis patients is associated with better survival and QOL, lower inflammation, and significantly less EPO use. RKF should be monitored routinely in hemodialysis patients. The development of methods to assess and preserve RKF is important and may improve dialysis care. Copyright (c) 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
BACKGROUND: Residual kidney function (RKF) is associated with improved survival in peritoneal dialysis patients, but its role in hemodialysis patients is less well known. Urine output may provide an estimate of RKF. The aim of our study is to determine the association of urine output with mortality, quality of life (QOL), and inflammation in incident hemodialysis patients. STUDY DESIGN: Nationally representative prospective cohort study. SETTING & PARTICIPANTS: 734 incident hemodialysis participants treated in 81 clinics; enrollment, 1995-1998; follow-up until December 2004. PREDICTOR: Urine output, defined as producing at least 250 mL (1 cup) of urine daily, ascertained using questionnaires at baseline and year 1. OUTCOMES & MEASUREMENTS: Primary outcomes were all-cause and cardiovascular mortality, analyzed using Cox regression adjusted for demographic, clinical, and treatment characteristics. Secondary outcomes were QOL, inflammation (C-reactive protein and interleukin 6 levels), and erythropoietin (EPO) requirements. RESULTS: 617 of 734 (84%) participants reported urine output at baseline, and 163 of 579 (28%), at year 1. Baseline urine output was not associated with survival. Urine output at year 1, indicating preserved RKF, was independently associated with lower all-cause mortality (HR, 0.70; 95% CI, 0.52-0.93; P = 0.02) and a trend toward lower cardiovascular mortality (HR, 0.69; 95% CI, 0.45-1.05; P = 0.09). Participants with urine output at baseline reported better QOL and had lower C-reactive protein (P = 0.02) and interleukin 6 (P = 0.03) levels. Importantly, EPO dose was 12,000 U/wk lower in those with urine output at year 1 compared with those without (P = 0.001). LIMITATIONS: Urine volume was measured in only a subset of patients (42%), but agreed with self-report (P < 0.001). CONCLUSIONS: RKF in hemodialysis patients is associated with better survival and QOL, lower inflammation, and significantly less EPO use. RKF should be monitored routinely in hemodialysis patients. The development of methods to assess and preserve RKF is important and may improve dialysis care. Copyright (c) 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Authors: K Ateş; G Nergizoğlu; K Keven; A Sen; S Kutlay; S Ertürk; N Duman; O Karatan; A E Ertuğ Journal: Kidney Int Date: 2001-08 Impact factor: 10.612
Authors: Louise M Moist; Friedrich K Port; Sean M Orzol; Eric W Young; Truls Ostbye; Robert A Wolfe; Tempie Hulbert-Shearon; Camille A Jones; Wendy E Bloembergen Journal: J Am Soc Nephrol Date: 2000-03 Impact factor: 10.121
Authors: Dana C Miskulin; Klemens B Meyer; Nicolaos V Athienites; Alice A Martin; Norma Terrin; Jane V Marsh; Nancy E Fink; Josef Coresh; Neil R Powe; Mike J Klag; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-02 Impact factor: 8.860
Authors: A W Wu; N E Fink; K A Cagney; E B Bass; H R Rubin; K B Meyer; J H Sadler; N R Powe Journal: Am J Kidney Dis Date: 2001-01 Impact factor: 8.860
Authors: J Craig Longenecker; Josef Coresh; Neil R Powe; Andrew S Levey; Nancy E Fink; Alice Martin; Michael J Klag Journal: J Am Soc Nephrol Date: 2002-07 Impact factor: 10.121
Authors: Tariq Shafi; Neil R Powe; Timothy W Meyer; Seungyoung Hwang; Xin Hai; Michal L Melamed; Tanushree Banerjee; Josef Coresh; Thomas H Hostetter Journal: J Am Soc Nephrol Date: 2016-07-19 Impact factor: 10.121
Authors: E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn Journal: Clin J Am Soc Nephrol Date: 2010-10-28 Impact factor: 8.237
Authors: Paungpaga Lertdumrongluk; Elani Streja; Connie M Rhee; Jongha Park; Onyebuchi A Arah; Steven M Brunelli; Allen R Nissenson; Daniel Gillen; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2014-04-26 Impact factor: 3.754